A randomized, controlled trial comparing darbepoetin alfa correction/maintenance dosing with weekly dosing for treating chemotherapy-induced anemia

Current Medical Research and Opinion

Volumn 23, Issue 6, 2007, Pages 1387-1401

  Kotasek, Dusan ^a   Canon, Jean Luc ^b   Mateos, Maria Victoria ^c   Hedenus, Michael ^d   Rossi, Greg ^e   Taylor, Kerry ^f  

^a Ashford Cancer Centre   (Australia)

^b Centre Hospitalier Notre Dame et Reine Fabiola   (Belgium)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^d SUNDSVALL HOSPITAL   (Sweden)

^e AMGEN INC   (United States)

^f Mater Misericordiae Hosp   (Australia)

Author keywords

Anemia; Darbepoetin alfa; Double blind method; Medical oncology; Randomized controlled trial

Indexed keywords

DOCETAXEL; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; RECOMBINANT ERYTHROPOIETIN; THALIDOMIDE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ASTHENIA; BACKACHE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HYPERTENSION; INJECTION SITE PAIN; INSOMNIA; LUNG EMBOLISM; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PAIN; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; FEMALE; HEMATINICS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; POLYPHARMACY; TREATMENT OUTCOME;

EID: 34347231580     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X188053     Document Type: Conference Paper

References (28)

1. Cella D, Dobrez D, Glaspy J. Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. Ann Oncol 2003;14:511-19
2. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-34
3. Herrington JD, Davidson SL, Tomita DK, et al. Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Am J Health Syst Pharm 2005;62:54-62
4. Schwartzberg LS, Yee LK, Senecal FM, et al. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist 2004;9:696-707
5. Cheer SM, Wagstaff AJ. Epoetin Beta: a review of its clinical use in the treatment of anaemia in patients with cancer. Drugs 2004;64:323-46
6. Hedenus M, Adriansson M, San Miguel J, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394-403
7. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-20
8. Glaspy J, Vadhan-Raj S, Patel R, et al. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. J Clin Oncol 2006;24:2290-7
9. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708-14
10. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004;40:2201-16
11. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002;100:2303-20
12. Rodgers GM, Cella D, Chanan-Khan A, et al. Clinical practice guidelines in oncology: cancer- and treatment-related anemia. v.2.2006 ed: National Comprehensive Cancer Network. http://www.nccn.org. Accessed August 23, 2006.
13. Amgen Inc. Aranesp® (Darbepoetin alfa) Package Insert. Thousand Oaks, CA; 2006.
14. Canon JL, Vansteenkiste J, Bodoky G, et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 2006;98:273-84
15. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001;84 Suppl 1:3-10
16. Egrie JC, Dwyer E, Browne JK, et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003;31:290-9
17. Hedenus M, Hansen S, Taylor K, et al. Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol 2002;119:79-86
18. Kotasek D, Steger G, Faught W, et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 2003;39:2026-34
19. Glaspy JA, Jadeja JS, Justice G, et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 2002;87:268-76
20. Glaspy JA, Jadeja JS, Justice G, et al. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease. Cancer 2003;97:1312-20
21. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997;34:13-19
22. Medical Dictionary for Regulatory Activities Terminology (MedDRA). Version 6.1, October 2003. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). MedDRA/MSSO resources page. Available at: http://www.meddramsso.com/MSSOWeb/ index.htm. Accessed March 3, 2007
23. Cella D, Eton DT, Lai JS, et al. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 2002;24:547-61
24. Hesketh PJ, Arena F, Patel D, et al. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. Cancer 2004;100:859-68
25. Justice G, Kessler JF, Jadeja J, et al. A randomized, multicenter study of subcutaneous and intravenous darbepoetin alfa for the treatment of chemotherapy-induced anemia. Ann Oncol 2005;16:1192-8
26. Amgen (Europe). Aranesp® (Darbepoetin alfa) Package Insert. Lucerne, Switzerland; 2004.
27. Glaspy J, Henry D, Patel R, et al. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer 2005;41:1140-9
28. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001;134:663-94